Acticor Biotech starts trial for heart attack drug Glenzocimab
Acticor Biotech's glenzocimab, a potential new drug to improve the long-term outcomes for heart attack patients will be trialed in the U.K.
Source: labiotech.eu
Page 31 - Cardiovascular Sciences News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Cardiovascular Sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Cardiovascular Sciences Today - Breaking & Trending Today
First clinical trial to test novel heart attack drug
The first clinical trial for new heart attack drug glenzocimab, will evaluate its ability to reduce heart damage following a heart attack.
Source: europeanpharmaceuticalreview.com
Acticor Biotech: World's First Clinical Trial to Test New Drug Glenzocimab for Heart Attacks
Regulatory News: Partnership between the University of Birmingham and Acticor Biotech (Paris:ALACT) will see patients with heart attacks treated with glenzocimab, a promising new class of drug
Source: finanznachrichten.de
Acticor Biotech: World's First Clinical Trial to Test New Drug Glenzocimab for Heart Attacks Seite 1
22.11.2022 - Regulatory News: Partnership between the University of Birmingham and Acticor Biotech (Paris:ALACT) will see patients with heart attacks treated with glenzocimab, a promising new class of drug for the first time. A potential new drug to improve the ... Seite 1
Source: wallstreet-online.de
Researchers make first bone marrow 'organoids' to capture key features of human bone marrow
Scientists from Oxford University and the University of Birmingham have made the first bone marrow 'organoids' that capture the key features of human bone marrow.
Source: news-medical.net